Skip to content
  • Saturday, 15 August 2026
  • 12:30 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Merck KGaA and Remepy Forge Groundbreaking Partnership to Pioneer "Hybrid Drugs" for Rare Cancers
Pharmaceutical R&D

Merck KGaA and Remepy Forge Groundbreaking Partnership to Pioneer "Hybrid Drugs" for Rare Cancers

Teuku Ryan Apr 28, 2026 0

In a move that signals a significant shift in pharmaceutical innovation, Merck KGaA has announced a strategic collaboration with Remepy,…

Read More
Pharmaceutical R&D

Merck KGaA Acquires JSR Life Sciences’ Chromatography Business to Bolster Biopharmaceutical Purification Capabilities

Teuku Ryan Apr 3, 2026 0

Germany-based Merck KGaA, a leading science and technology company, has officially completed its previously announced acquisition of the chromatography business…

Read More
Salk Institute Researchers Identify BCL6 Protein as Key to Preventing Muscle Loss During GLP-1 Weight Management and AgingSalk Institute Identifies Med14 Protein as Key Regulator for GLP-1 Agonists’ Long-Term Pancreatic Health BenefitsOptovolution: Harnessing Light and Evolution for Dynamic Proteins and Cellular ComputationBeyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactLLMOps in 2026: The 10 Tools Every Team Must HaveThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ